{
    "ticker": "NKTR",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage immunotherapy company focused on harnessing the power of the immune system to treat cancer, infectious diseases, and autoimmune disorders. Founded in 2015 and headquartered in Culver City, California, NantKwest is known for its innovative approach to developing cell-based therapies. The company's lead product candidate, NK cell therapy, is designed to utilize natural killer (NK) cells from the patient's own immune system, engineered to enhance their ability to target and destroy cancer cells. NantKwest's proprietary technology platform enables the creation of off-the-shelf NK cell therapies, which have the potential to provide rapid and effective treatment options for patients. The company is actively engaged in multiple clinical trials aimed at evaluating the safety and efficacy of its therapies across various types of cancer, including solid tumors and hematological malignancies. With a strong commitment to advancing cancer treatment, NantKwest collaborates with leading research institutions and seeks to leverage cutting-edge science to bring new therapies to market. The company's mission is to transform the landscape of cancer treatment by providing innovative and effective immune-oncology solutions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "C. Thomas Caskey",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://investors.nantkwest.com",
    "key_executives": [
        {
            "name": "C. Thomas Caskey",
            "position": "CEO"
        },
        {
            "name": "James M. E. F. B. McCune",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "NK Cell Therapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore NantKwest, Inc., a leader in immunotherapy focused on harnessing the immune system to treat cancer and other diseases through innovative cell-based therapies.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "NK Cell Therapy",
            "Cancer Treatment",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does NantKwest do?",
            "answer": "NantKwest is a clinical-stage immunotherapy company developing NK cell therapies for cancer and other diseases."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "C. Thomas Caskey is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What is the lead product of NantKwest?",
            "answer": "The lead product candidate of NantKwest is NK cell therapy."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "NVTA",
        "CRIS",
        "KITE",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "MRNA",
        "PFE"
    ]
}